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amounted to 178 514 euro. The average hospitalisation costs per patient was 2380 
euro. ConClusions: Our analysis demonstrates that therapies of drug-induced, 
adverse skin reactions induced by antibiotics generate considerable costs, both for 
the payer and the service provider. The costs, which are incurred by either party, 
are comparable, providing evidence that the pricing of procedures, proposed by the 
public payer in Poland and valid since 2012, has been adequate to the expenses, 
borne by the service provider.
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objeCtives: Through analyzing the main immunization strategies for preventing 
mother-to-child transmission of HBV in China, figure out the optimized strategy 
which fit the current situation of China based on constructed Decision Tree-Markov 
model and cost-benefit analyses. Methods: The multilevel decision tree-markov 
model was constructed by TreeAge Pro Software 2011, which could simulate the 
prognosis of HBV disease after various immunization strategies for preventing 
mother-to-child transmission of HBV; In this model, extracted parameters were 
needed, including vaccine inoculation rate, protective rate of various immuniza-
tion protocol, the prognosis of disease and its probabilities, the financial burden 
of various disease condition, from important published researches by literature 
review; then evaluated each immunization strategy by cost-benefit analyses, and 
examined the stability of test results, the parameters which influence the results 
greatly through sensitivity analysis and threshold analysis. Results: Currently 
there were 8 immunization strategies for preventing mother-to-child transmission 
of HBV in China. The cost of each immunization strategy varied from 8162.8 RMB 
(1316.6US$) to 14840.4 RMB(2393.6US$), which included the vaccine inoculation and 
infection and therapy cost if immunization failed. The benefit of each strategy, 
which was assessed by the avoiding financial burden by immunization, varied from 
50801.9 RMB (8193.8US$) to 73801.0 RMB (11903.4US$). The BCR of each strategies 
varied from 3.7 to 19.3. The sensitive factors were vaccination protection rate, vac-
cination inoculation rate, the costs of HBV infection every year. ConClusions: 
Comparatively, the optimized strategy in China was giving the newborns of HBsAg 
positive mother an 200IU HBIG IM injection within 24 hrs after birth, then 3 shots 10 
μ g Hepatitis B Vaccine in accordance with 0-1-6 procedure (BCR= 19.3). The decision 
tree -Markov model has good applicability and reliability for quantitative economic 
evaluation and optimization of hepatitis B vaccination strategies for preventing 
mother-to-child transmission.
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objeCtives: To evaluate published cost-effectiveness analyses (CEA) assessing 
nucleos(t)ide analogues (NAs), interferon, and pegylated interferon for chronic 
hepatitis B (CHB). Methods: Main medical databases in both English and Chinese 
were searched up to October 2012 to identify eligible studies for data extraction. 
The base case incremental costeffectiveness ratio (ICER) per quality-adjusted 
life year (QALY) was adjusted to 2011 local currency value and presented by the 
ratio to 2011 gross domestic product per capita (GDPPC). Simple linear regression 
analyses took adjusted ICER per QALY as dependent variable to assess the cost-
effectiveness of antiviral therapy when compared to lamivudine. Results: 81 
studies published in English and 18 studies published in Chinese were identified. 
When compared to no treatment, all NAs were associated with an ICER per QALY 
of less than 1 GDPPC in high or middle-income countries. When compared to 
lamivudine, entecavir was associated with an ICER per QALY of less than 1 GDPPC 
in high or middle-income countries. Simple linear regression analyses observed 
significantly reduced ICER per QALY associated with entecavir (coefficient -1.450, 
P= 0.018) but significantly increased ICER per QALY associated with interferon 
(coefficient 5.583, P< 0.001) or adefovir (coefficient 2.354, P< 0.001) when compared 
to lamivudine. Telbivudine, tenofovir and pegylated interferon did not have sig-
nificant impact on ICER per QALY when lamivudine was the reference. One study 
published in Chinese was considered high quality and reported the lowest ICER 
per QALY associated with entecavir when compared to no treatment in patients 
with positive or negative hepatitis B e antigen (HBeAg). ConClusions: When 
compared to no treatment, NAs were highly cost-effective for CHB in high or 
middle-income countries. When compared to lamivudine, entecavir was the most 
cost-effective treatment among NAs. Entecavir was also the most cost-effective 
NA when compared to no treatment in Chinese patients with CHB, irrespective 
of their HBeAg status.
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objeCtives: The Pneumococcal disease is a major cause of morbidity and mortal-
ity in pediatrics, and it leads to serious health as well as economic burden on the 
national health care system. In Korea, both 13-valent and 10-valent pneumococcal 
conjugate vaccines are currently used for the prevention of pneumococcal infec-
tions for Pediatrics. This study aims to evaluate the long-term economic and clini-
cal impact of PCV-13 versus PCV-10 vaccination in prevention of IPD, pneumonia 
and acute otitis media (AOM) from health care system perspective. Methods: 
A Markov cohort model with a 10-year time horizon was used to estimate the effect 
of infant vaccination with PCV-13 versus PCV-10. Using this model, we considered 
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objeCtives: To compare clinical outcomes and hospital costs in patients receiving 
empirical treatment of hospital-acquired pneumonia (HAP) with vancomycin or lin-
ezolid in Chinese patients. Methods: Patients receiving empirical treatment with 
vancomycin or linezolid for HAP from 2008 to 2012 in a tertiary hospital in Shanghai 
were identified and linked with hospital administration databases for retrospective 
data extraction. Best matching pairs identified by propensity score methods for 
the two antibiotics were compared on HAP-related clinical response, in-hospital 
mortality, and allocation of hospital costs. The comparisons on clinical outcomes 
were confirmed by multiple logistic regression analyses with adjusting unbalanced 
baseline variables between matched pairs. Results: 60 propensity score matched 
pairs for the two antibiotics were identified. Empirical treatment with vancomycin 
or linezolid had comparable responses at the end of treatment (clinical cure: 30.0% 
vs. 31.7%, p= 0.847; treatment failure: 55.0% vs. 45.0%, p= 0.289). However, vanco-
mycin was associated with significantly lower in-hospital mortality than linezolid 
(3.3% vs. 18.3%, p= 0.013). Comparable risk of treatment failure between the two 
antibiotics (odds ratio (OR) 1.139, p= 0.308) and lower risk of in-hospital mortality 
associated with vancomycin (OR 0.186, p= 0.055) were confirmed after adjustment 
of unbalanced baseline variables between matched pairs. Vancomycin was associ-
ated with lower total hospital costs than linezolid (RMB 113,160 vs. RMB 133,825, 
p= 0.076; 1 RMB = 0.16 US dollars) likely because of significantly lower acquisition 
cost of vancomycin (median RMB 2,880 vs. RMB 8,194, p< 0.001) and other hospital 
costs unrelated to drugs, medical examinations, and medical supplies (median RMB 
27,686 vs. RMB 44,826, p= 0.006). ConClusions: Empirical treatment with vanco-
mycin and linezolid for HAP had comparable treatment response but in-hospital 
mortality associated with vancomycin was lower in Chinese patients. Significantly 
lower antibiotic acquisition cost and other hospital costs unrelated to drugs, exams, 
and supplies likely made substantial contribution to the reduced hospital costs 
associated with vancomycin.
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objeCtives: Incidence of hepatitis C viral infection (HCV) is increasing in China 
and HCV represents considerable disease burden to the country. As there is no 
published data on treatment costs to HCV in China, this study reports key findings 
from a recent survey to examine treatment costs in the country. Methods: A cross 
sectional survey was conducted in 2012 among 29 hospitals across China. Data were 
collected from patients who visited either outpatient or inpatient settings, including 
patient demographics, coverage of health insurance, and costs to treat HCV related 
visits. Results were analyzed by descriptive statistics. Results: A total of 1,116 
patients participated into this survey. Males (52.6%) were slightly more than females. 
The average age was 45.5 years old and 49.9 years old for outpatient and inpatient 
cases, respectively. Patients who were in their productive age groups (30 to 49 years 
old) are the majority (48.7%). While most of the inpatient cases had health insurance 
coverage, 49.6% of the outpatient cases were out of pocket. Medium cost for an HCV 
related hospital admission was 8,212 RMB (or 1,369 USD); of which medications, 
both western and traditional medicines, cost 61.1%. This study found that 
more advanced the disease progress, higher costs to the condition: for chronic 
HCV, cirrhosis, and hepatocellular carcinoma, the medium costs were 8,111 
RMB (1,351 USD), 8,399 RMB (1,399 USD), and 14,425 RMB (2,404 USD), respec-
tively. ConClusions: Key findings suggest that (1) a better disease management 
strategy help to improve the national economy in long term; (2) the needs for an 
early and successful treatment to these patients to reduce the finance burden; and 
(3) an improvement of health policy, especially on health insurance, would result 
in better treatment and disease management to HCV in China.
PIN16
dIrEct costs of trEatmENt of sKIN drug rEactIoNs INducEd By 
aNtIBIotIcs IN PErsPEctIvE of PuBlIc PayEr aNd sErvIcE ProvIdEr
Wisniewska N.1, Jahnz-Rozyk K.M.1, Paluchowska E.B.1, Owczarek W.1, Szkultecka-Debek M.2
1Military Institute of Medicine, Warsaw, Poland, 2Department of Dermatology, Military Institute of 
Medicine, Warsaw, Poland
objeCtives: The aim was to analyze the direct costs of treatment of skin drug 
reactions induced by antibiotics in perspective of public payer (National Health 
Fund) and service provider. Methods: We analyzed retrospectively data from 164 
patients hospitalized in the Department of Dermatology, Military Medical Institute 
in Warsaw (from 2002 to 2012) due to skin drug reactions. The analysis was based 
on data derived from the patients’ medical charts and cost data provided by the 
hospital accounting department. The hospitalization costs by National Health 
Fund (NHF) were calculated based on the prices for medical services established 
by the NHF on the basis of a contract with the Military Institute of Medicine (2012 
year). Results: In the study group the most common cause of cutaneous drug 
reactions were antibiotics (45 %) including beta lactamase antibiotics, antibiotics 
with beta-lactamase inhibitor, clindamycins, flourochinolons. The total cost of hos-
pitalisation, based on the scores, assigned by the National Health Fund was 177 629 
euro. The average cost per patient was 2368 euro. The total costs of hospitalisation 
in the analysed period, incurred by the Military Institute of Medicine and calculated 
according to the internal pricelist for the year 2012 for the analysed study group 
